Pulmonary zygomycosis

Seminars in Respiratory and Critical Care Medicine

Volumn 29, Issue 2, 2008, Pages 111-120

  Pyrgos, Vasilios ^a   Shoham, Shmuel ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Fungal infection; Mucormycosis; Pulmonary infection; Zygomycosis

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; DEFEROXAMINE; ECHINOCANDIN; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; POSACONAZOLE; RIFAMPICIN; TERCONAZOLE; TETRACYCLINE;

CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; LUNG BIOPSY; LUNG DISEASE; MONOTHERAPY; MUCORMYCOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOFT TISSUE;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; RISK FACTORS; ZYGOMYCOSIS;

EID: 41149088402     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1063850     Document Type: Review

References (107)

1. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-569
2. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006;20:581-607
3. Walsh TJ, Renshaw G, Andrews J, et al. Invasive zygomycosis due to Conidiobolus incongruus. Clin Infect Dis 1994;19:423-430
4. Tan DC, Hsu LY, Koh LP, Goh YT, Koh M. Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia. Br J Haematol 2005;129:447
5. Walker SD, Clark RV, King CT, Humphries JE, Lytle LS, Butkus DE. Fatal disseminated Conidiobolus coronatus infection in a renal transplant patient. Am J Clin Pathol 1992;98:559-564
6. van den Berk GE, Noorduyn LA, van Ketel RJ, van Leeuwen J, Bemelman WA, Prins JM. A fatal pseudotumour: disseminated basidiobolomycosis. BMC Infect Dis 2006;6:140
7. Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection: occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA 1979;242:272-274
8. Sheldon DL, Johnson WC. Cutaneous mucormycosis: two documented cases of suspected nosocomial cause. JAMA 1979;241:1032-1034
9. Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 1996;348:441-443
10. Tanabe Y, Watanabe MM, Sugiyama J. Evolutionary relationships among basal fungi (Chytridiomycota and Zygomycota): insights from molecular phylogenetics. J Gen Appl Microbiol 2005;51:267-276
11. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998;27:1138-1147
12. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-653
13. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999;37:1732-1738
14. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-989
15. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus- active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360
16. Christiaens G, Hayette MP, Jacquemin D, Melin P, Mutsers J, De Mol P. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect 2005;61:88
17. Kapadia S, Polenakovik H. Cutaneous zygomycosis following attempted radial artery cannulation. Skinmed 2004;3:336-338
18. Khardori N, Hayat S, Rolston K, Bodey GP. Cutaneous Rhizopus and Aspergillus infections in five patients with cancer. Arch Dermatol 1989;125:952-956
19. Cocanour CS, Miller-Crotchett P, Reed RL, Johnson PC, Fischer RP. Mucormycosis in trauma patients. J Trauma 1992;32:12-15
20. Parker C, Kaminski G, Hill D. Zygomycosis in a tattoo, caused by Saksenaea vasiformis. Australas J Dermatol 1986;27:107-111
21. Vaideeswar P, Pandit SP. Primary zygomycosis of the pericardium in an immunocompetent host. Mycoses 2007;50:232-234
22. Jayasuriya NS, Tilakaratne WM, Amaratunga EA, Ekanayake MK. An unusual presentation of rhinofacial zygomycosis due to Cunninghamella sp. in an immunocompetent patient: a case report and literature review. Oral Dis 2006;12:67-69
23. O'Connell MA, Pluss JL, Schkade P, Henry AR, Goodman DL. Rhizopus-induced hypersensitivity pneumonitis in a tractor driver. J Allergy Clin Immunol 1995;95:779-780
24. Wimander K, Belin L. Recognition of allergic alveolitis in the trimming department of a Swedish sawmill. Eur J Respir Dis Suppl 1980;107:163-167
25. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-312
26. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 1993;91:1979-1986
27. Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med 1989;87:468-471
28. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994;45:667-671
29. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006;50:3968-3969
30. Weems JJ Jr, Davis BJ, Tablan OC, Kaufman L, Marione WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 1987;8:71-75
31. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005;73:778-783
32. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989;47:243-271
33. Diamond RD, Haudenschild CC, Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982;38:292-297
34. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-1838
35. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982;31:1109-1114
36. Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982;38:1123-1129
37. Marx RS, Forsyth KR, Hentz SK. Mucorales species activation of a serum leukotactic factor. Infect Immun 1982;38:1217-1222
38. Van Campenhout A, Van Campenhout C, Lagrou AR, Manuel YKB. Effects of in vitro glycation on Fe3 + binding and Fe3 + isoforms of transferrin. Clin Chem 2004;50:1640-1649
39. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18:660-667
40. Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992;7:931-938
41. Feeley MA, Righi PD, Davis TE, Greist A. Mucormycosis of the paranasal sinuses and septum. Otolaryngol Head Neck Surg 1999;120:750
42. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000;33:349-365
43. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994;39:3-22
44. Greenberg MR, Lippman SM, Grinnell VS, Colman MF, Edwards JE. Computed tomographic findings in orbital Mucor. West J Med 1985;143:102-103
45. Guevara N, Roy D, Dutruc-Rosset C, Santini J, Hofman P, Castillo L. Mucormycosis: early diagnosis and treatment. Rev Laryngol Otol Rhinol (Bord) 2004;125:127-131
46. Hofman V, Castillo L, Betis F, Guevara N, Gari-Toussaint M, Hofman P. Usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management. Pathology 2003;35:212-216
47. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005;41:60-66
48. Dykhuizen RS, Kerr KN, Soutar RL. Air crescent sign and fatal haemoptysis in pulmonary mucormycosis. Scand J Infect Dis 1994;26:498-501
49. Coelho Filho JC, Pereira J, Rabello Junior A. Mediastinal and pulmonary entomophthoromycosis with superior vena cava syndrome: case report. Rev Inst Med Trop Sao Paulo 1989;31:430-433
50. Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest 1979;75:525-526
51. Green WR, Bouchette D. Pleural mucormycosis (zygomycosis). Arch Pathol Lab Med 1986;110:441-442
52. Helenglass G, Elliott JA, Lucie NP. An unusual presentation of opportunistic mucormycosis. Br Med J (Clin Res Ed) 1981;282:108-109
53. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997;168:1541-1548
54. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med 1978;299:1115-1118
55. Prevoo RL, Starink TM, de Haan P. Primary cutaneous mucormycosis in a healthy young girl: report of a case caused by Mucor hiemalis Wehmer. J Am Acad Dermatol 1991;24:882-885
56. Jain JK, Markowitz A, Khilanani PV, Lauter CB. Localized mucormycosis following intramuscular corticosteroid: case report and review of the literature. Am J Med Sci 1978;275:209-216
57. Burkitt DP, Wilson AM, Jelliffe DB. Subcutaneous phycomycosis: a review of 31 cases seen in Uganda. BMJ 1964;1:1669-1672
58. Cefai C, Elliott TS, Nutton RW, Lockett AE, Pooley J. Zygomycetic gangrenous cellulitis. Lancet 1987;2:1337-1338
59. Vainrub B, Macareno A, Mandel S, Musher DM. Wound zygomycosis (mucormycosis) in otherwise healthy adults. Am J Med 1988;84:546-548
60. Patino JF, Castro D, Valencia A, Morales P. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg 1991;15:240-247
61. Andresen D, Donaldson A, Choo L, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 2005;365:876-878
62. Thomson SR, Bade PG, Taams M, Chrystal V. Gastrointestinal mucormycosis. Br J Surg 1991;78:952-954
63. Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996;22:521-524
64. Atkinson JB, Connor DH, Robinowitz M, McAllister HA, Virmani R. Cardiac fungal infections: review of autopsy findings in 60 patients. Hum Pathol 1984;15:935-942
65. Virmani R, Connor DH, McAllister HA. Cardiac mucormycosis: a report of five patients and review of 14 previously reported cases. Am J Clin Pathol 1982;78:42-47
66. Naumann R, Kerkmann ML, Schuler U, Daniel WG, Ehninger G. Cunninghamella bertholletiae infection mimicking myocardial infarction. Clin Infect Dis 1999;29:1580-1581
67. al-Abbadi MA, Russo K, Wilkinson EJ. Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: a case report and review of the literature. Pediatr Pulmonol 1997;23:222-225
68. Deshpande AH, Munshi MM. Rhinocerebral mucormycosis diagnosis by aspiration cytology. Diagn Cytopathol 2000;23:97-100
69. Glazer M, Nusair S, Breuer R, Lafair J, Sherman Y, Berkman N. The role of BAL in the diagnosis of pulmonary mucormycosis. Chest 2000;117:279-282
70. Gonzalez C, Antachopoulos C, Shoham S, Walsh TJ. Zygomycosis. In: Scheid W, Hooper DC and Hughes JM, eds. Emerging Infections 7. Washington, DC: ASM Press; 2006
71. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301
72. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001;125:375-378
73. Harrington SM, Kasai M, Francesconi A, et al. Design and validation of a quantitative real-time PCR assay for Rhizopus spp. and Mucor spp. in experimental pulmonary zygomycosis. 107th Annual Meeting of the American Society for Microbiology; May 21-25, 2007; Toronto, Canada. Abstr F-0352007:298
74. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-1050
75. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-e65
76. Baker RD. Mucormycosis: a new disease? J Am Med Assoc 1957;163:805-808
77. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997;99:331-336
78. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997;175:1012-1015
79. Roilides E, Pizzo PA. Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts. Hematol Oncol Clin North Am 1993;7:841-864
80. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23
81. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005;191:1180-1187
82. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004;23:769-773
83. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997;24:192-196
84. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994;34:226-232
85. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981;304:1185-1189
86. Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000;14:329-339
87. Boyle JA. Controlled trials of amphotericin B lipid complex. Clin Infect Dis 2000;31:1117-1118
88. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702-708
89. Walsh TJ, Hiemenz JVV, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396
90. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-3496
91. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-1297
92. Adler DE, Milhorat TH, Miller JI. Treatment of rhinocerebral mucormycosis with intravenous interstitial, and cerebrospinal fluid administration of amphotericin B: case report. Neurosurgery 1998;42:644-649
93. Gaviria JM, Grohskopf LA, Barnes R, Root RK. Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach. Clin Infect Dis 1999;28:160-161
94. Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities. Ophthal Plast Reconstr Surg 2001;17:62-66
95. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in the era of Aspergillus-active antifungal therapy in a tertiary care cancer center: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1359
96. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-133
97. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-255
98. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005;49:830-832
99. Paterson PJ, Seaton S, Prentice HG, Kibbler CC. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003;52:873-876
100. Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years' experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope 1984;94:1060-1062
101. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 1997;107:855-862
102. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999;159:1301-1309
103. Langford JD, McCartney DL, Wang RC. Frozen section-guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol 1997;124:265-267
104. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988;10:551-559
105. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005;11:515-517
106. Barratt DM, Van Meter K, Asmar P, et al. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model. Antimicrob Agents Chemother 2001;45:3601-3602
107. Barchiesi F, Spreghini E, Santinelli A, et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007;51:73-77